Chapter

Key Takeaways

From 10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE by 10 Cancer Treatment Approvals From September 2026 and What They Mean for You

Concepts

1. Treatment Findings

   "Camizestrant plus a CDK4/6 inhibitor established ctDNA-detected emergent ESR1 mutation as an on-treatment switch trigger, improving PFS versus continuing initial endocrine therapy.\n\nSevabertinib ac

2. Treatment Access

   "Tarlatamab initiation logistics improved with shortened post-dose monitoring (6–8 hours) while preserving proximity/caregiver requirements, potentially expanding feasibility beyond tertiary centers.\

3. Approval Withdrawal

   "Withdrawal of adagrasib plus cetuximab for KRAS G12C colorectal cancer underscored the vulnerability of accelerated approvals when confirmatory trials fail to demonstrate survival advantage."

4. September Options

   "September brought new options for breast, lung, kidney, bile duct, skin and neuroendocrine cancers, plus a brain tumor scan and easier lung cancer treatment.\n\nSeptember 2026 was a busy month for th